$REVB

Revelation Biosciences, Inc. has begun GMP manufacturing of GEMINI and a placebo to provide clinical drug supply for its later-stage clinical studies. This move is a critical step in advancing Revelation's pipeline and accelerating timelines for upcoming clinical programs, including randomized, double-blinded, placebo-controlled studies. The Company recently met with the FDA to discuss the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury.